Digest Network Come funziona
Network
/
Società
In
Non verificato

Incyte

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

92 comunicati stampa

Guarda tutti i comunicati
06/03/2026
Industria
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
Fonte
Incyte
Emittente
Business Wire
1.00
0
17/02/2026
Web e Social Network
Eventi
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Incyte to Present at Upcoming Investor Conferences
Fonte
Incyte
Emittente
Business Wire
1.00
0
10/02/2026
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
Fonte
Incyte
Emittente
Business Wire
1.00
0
30/01/2026
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Industria
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
Fonte
Incyte
Emittente
Business Wire
1.00
0
27/01/2026
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
Fonte
Incyte
Emittente
Business Wire
1.00
0
05/01/2026
Scienza
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Industria
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
Fonte
Incyte
Emittente
Business Wire
1.00
0
22/12/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Fonte
Incyte
Emittente
Business Wire
1.00
0
22/12/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
Fonte
Incyte
Emittente
Business Wire
1.00
0
18/12/2025
Eventi
Web e Social Network
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Incyte to Present at Upcoming Investor Conference
Fonte
Incyte
Emittente
Business Wire
1.00
0
18/12/2025
Eventi
Web e Social Network
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Incyte to Present at Upcoming Investor Conference
Fonte
Incyte
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0